Back to today’s briefing

Story perspectives

Lawmakers Alarmed Over 23andMe's Data Privacy Amid Sale

6/12/2025

47 7

Summary

Story summary

The House Committee on Oversight scrutinized 23andMe's bankruptcy sale, voicing alarm over the potential exposure of genetic data from 15 million customers. Lawmakers are determined to shield this sensitive information from foreign threats. Meanwhile, Regeneron Pharmaceuticals is set to acquire 23andMe, assuring customers that their privacy will remain a top priority throughout the transition.

History

Historical Context

The Genetic Information Nondiscrimination Act (GINA) was enacted in 2008 to prevent discrimination based on genetic data, addressing growing concerns about privacy. Companies like 23andMe, founded in 2006, have since collected genetic information from over 15 million customers. Current scrutiny by the House Committee on Oversight highlights ongoing challenges in protecting personal data as biotechnology evolves.

1 of 2

Story summary

The House Committee on Oversight scrutinized 23andMe's bankruptcy sale, voicing alarm over the potential exposure of genetic data from 15 million customers. Lawmakers are determined to shield this sensitive information from foreign threats. Meanwhile, Regeneron Pharmaceuticals is set to acquire 23andMe, assuring customers that their privacy will remain a top priority throughout the transition.

1 / 2